Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New CMV vaccine candidate enters first human tests

NCT ID NCT06145178

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine called SPYVLP01 designed to protect against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weak immune systems. The study involves 120 healthy adults aged 18 to 50 and will check if the vaccine is safe and triggers an immune response, with or without added adjuvants (boosters). Since this is a Phase 1 trial, the main focus is on safety, not yet on proving the vaccine prevents infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SPYVLP01 vaccine
What this could lead to
If successful, this could lead to a vaccine that prevents cytomegalovirus (CMV) infection, protecting vulnerable people like newborns and those with weakened immune systems.
What could go wrong
This is an early Phase 1 trial with only 120 healthy adults, so it's too soon to know if the vaccine works. The main goal is safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

120 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male and female adult volunteers aged 18 to 50 years with a body mass index (BMI) of 19 to 32 kg/m2 * Written informed consent before initiation of any study-specific procedures * Willing and able to understand and comply with study requirements * Women of childbearing potential must have a negative pregnancy test at screening and prior dose 1 of vaccine. * Women of childbearing potential must agree to practice a highly effective form of contraception continuously until 90 days after receiving the last immunization. * Women of childbearing potential must agree not to donate eggs from screening visit and continuously until 90 days after receiving the last immunization * Men must agree to practice a highly effective form of contraception with their female partner of childbearing potential from screening visit and continuously until 90 days after receiving the last immunization * Men must be willing to refrain from sperm donation, from screening visit and continuously until 90 days after receiving the last immunization * All participants must agree not to be vaccinated with any vaccine other than the study vaccine during the study, starting after screening visit and continuously until 28 days after receiving the last immunization Exclusion Criteria * Any acute illness, with or without fever within 72 hours prior to the first immunization * Pregnancy, lactation, or intention to become pregnant during the study * Have a known allergy, hypersensitivity, or intolerance to the planned Investigational Medicinal Product (IMP), adjuvants, and including any excipients of the IMP * Have any medical condition or any major surgery within the past 5 years which could compromise their well-being if they participate in the study, or that could prevent, limit, or confound the protocol-specified assessments * Have any surgery planned during the study, starting after screening and continuously until at least 90 days after receiving the last immunization * Any confirmed or suspected immunosuppressive or immunodeficient state and chronic immunosuppressant medication within the past 6 months * Received any live or inactivated vaccination within 6 months prior to screening or other vaccinations within the 28 days prior to screening * Have a history of hypersensitivity or serious reactions to previous vaccinations or a history of Guillain-Barré Syndrome within 6 weeks following a previous vaccination * Had administration of any immunoglobulins and/or any blood products within the 3 months prior to screening * Had administration of another IMP including vaccines within 90 days or 5 half-lives prior to screening (Visit 1) * Hepatitis B surface antigen detected in serum at screening * Seropositive for hepatitis C virus at screening * Have a history of or suspected immunosuppressive condition, acquired or congenital * Symptoms of COVID-19 within 30 days prior to screening * Alcohol or substance abuse that might interfere with the study conduct or completion * Consume more than 25 units of alcohol per week * Concurrent involvement in another clinical study or planned involvement during the study period * Prior receipt of an investigational vaccine * History of narcolepsy * Any abnormality or permanent body art (e.g., tattoo) that would obstruct the ability to observe local reactions at the injection site * Have had any blood loss \> 450 mL within the 3 months (90 days) prior to screening or plan to donate blood during the study * Anticipating the need for immunosuppressive treatment within the next 6 months * Inability to contact the participant's general practitioner to confirm medical history

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medicines Evaluation Unit

    Manchester, United Kingdom

  • Velocity Bristol

    Bristol, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.